TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

HOMATROPINE METHYLBROMIDE
Approved 1983-03-03
9
Indications
--
Phase 3 Trials
43
Years on Market

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE Approval History

Loading approval history...

What HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE Treats

1 indications

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE is approved for 1 conditions since its original approval in 1983. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cough
Source: FDA Label

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE Boxed Warning

ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME (NOWS) See full prescribing information for complete boxed warning. Addiction, Abuse, and Misuse Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution (Syrup) exposes patients and other users to the risks of opioid ad...

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE FDA Label Details

Pro

Indications & Usage

Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution (Syrup) are indicated for the symptomatic relief of cough in adult patients 18 years of age and older. Limitations of Use: Not indicated for pediatric patients under 18 years of age [ see Use in Specific Populations ]. Contraindicated in pediatric patients less than 6 years of age [see Contraindications ]. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions ], reserve Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution (Syrup) for use in adult...

⚠️ BOXED WARNING

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME (NOWS) See full presc...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.